NASDAQ:PODD Insulet - PODD Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Insulet Co. Please log in to your account or sign up in order to add this asset to your watchlist. $314.93 +4.76 (+1.53%) (As of 03/27/2023 04:00 PM ET) Add Compare Share Share Today's Range$308.52▼$314.9450-Day Range$276.36▼$326.0352-Week Range$181.00▼$326.74Volume776,158 shsAverage Volume858,624 shsMarket Capitalization$21.90 billionP/E Ratio5,248.83Dividend YieldN/APrice Target$317.82 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Insulet MarketRank™ ForecastAnalyst RatingModerate Buy2.55 Rating ScoreUpside/Downside1.5% Upside$317.82 Price TargetShort InterestHealthy3.67% of Shares Sold ShortDividend StrengthN/ASustainability-1.20Upright™ Environmental ScoreNews Sentiment0.69Based on 5 Articles This WeekInsider TradingSelling Shares$13.65 M Sold Last QuarterProj. Earnings Growth56.59%From $1.29 to $2.02 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.95 out of 5 starsMedical Sector582nd out of 995 stocksSurgical & Medical Instruments Industry55th out of 103 stocks 1.3 Analyst's Opinion Consensus RatingInsulet has received a consensus rating of Buy. The company's average rating score is 2.55, and is based on 6 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $317.82, Insulet has a forecasted upside of 1.5% from its current price of $313.26.Amount of Analyst CoverageInsulet has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.67% of the outstanding shares of Insulet have been sold short.Short Interest Ratio / Days to CoverInsulet has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Insulet has recently increased by 6.25%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInsulet does not currently pay a dividend.Dividend GrowthInsulet does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInsulet has received a 80.74% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Insulin pumps" product. See details.Environmental SustainabilityThe Environmental Impact score for Insulet is -1.20. Previous Next 3.2 News and Social Media Coverage News SentimentInsulet has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Insulet this week, compared to 4 articles on an average week.Search Interest31 people have searched for PODD on MarketBeat in the last 30 days. This is an increase of 417% compared to the previous 30 days.MarketBeat Follows7 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insulet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,647,895.00 in company stock.Percentage Held by InsidersOnly 0.90% of the stock of Insulet is held by insiders. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Insulet are expected to grow by 56.59% in the coming year, from $1.29 to $2.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insulet is 5,221.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 115.69.Price to Earnings Ratio vs. SectorThe P/E ratio of Insulet is 5,221.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 97.57.Price to Book Value per Share RatioInsulet has a P/B Ratio of 45.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Insulet (NASDAQ:PODD) StockInsulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.Read More Receive PODD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter. Email Address PODD Stock News HeadlinesMarch 27, 2023 | americanbankingnews.comComparing Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) & Insulet (NASDAQ:PODD)March 20, 2023 | finance.yahoo.comShould You Invest in Insulet Corporation (PODD)?March 27, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.March 17, 2023 | finance.yahoo.comInsulet (PODD) Stock Moves -1.05%: What You Should KnowMarch 16, 2023 | finance.yahoo.comInsulet (PODD) Gains But Lags Market: What You Should KnowMarch 14, 2023 | finance.yahoo.comCompany News for Mar 14, 2023March 3, 2023 | finance.yahoo.comShould You Hold Insulet Corporation (PODD)?February 28, 2023 | finance.yahoo.comInsulet (PODD) Upgraded to Buy: What Does It Mean for the Stock?March 27, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.February 28, 2023 | finance.yahoo.comIs Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think "Yes"February 23, 2023 | finance.yahoo.comInsulet (PODD) Q4 Earnings and Revenues Beat EstimatesFebruary 23, 2023 | finance.yahoo.comCORRECTING and REPLACING Insulet Reports Full Year 2022 Revenue Increase of 19% (22% constant currency1) and Fourth Quarter 2022 Revenue Increase of 20% Year-Over-Year (23% constant currency)February 21, 2023 | finance.yahoo.comHighly Anticipated Omnipod® 5 Real-World Evidence to be Presented at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)February 14, 2023 | finance.yahoo.comInsulet Acquires Assets of Automated Glucose Control LLC (AGC)February 13, 2023 | finance.yahoo.comInsulet Corporation (NASDAQ:PODD) Delivered A Weaker ROE Than Its IndustryFebruary 13, 2023 | businesswire.comInsulet Acquires Insulin Pump Patents from Bigfoot Biomedical as Both Companies Prioritize Improved Insulin Delivery TechnologiesFebruary 10, 2023 | finance.yahoo.comInsulet (PODD) to Report Q4 Earnings: What's in the Cards?February 1, 2023 | finance.yahoo.comInsulet (PODD) Outpaces Stock Market Gains: What You Should KnowJanuary 25, 2023 | finance.yahoo.comInsulet (PODD) Dips More Than Broader Markets: What You Should KnowJanuary 17, 2023 | finance.yahoo.comDow Jones Futures Drop Ahead Of Manufacturing Data; Goldman Sachs Slides On Earnings MissJanuary 16, 2023 | finance.yahoo.comDow Jones Futures Fall With U.S. Markets Closed For MLK Holiday; Tesla's Big TransitionJanuary 13, 2023 | finance.yahoo.comInsulet (PODD) Stock Sinks As Market Gains: What You Should KnowJanuary 12, 2023 | finance.yahoo.comHow IBD Stock Of The Day Insulet Built A 'Moat' To Keep Out RivalsJanuary 12, 2023 | finance.yahoo.comInsulet to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023January 9, 2023 | finance.yahoo.comInsulet (PODD) Gains As Market Dips: What You Should KnowJanuary 2, 2023 | finance.yahoo.comInsulet Corporation (PODD) Stock Historical Prices & Data - Yahoo FinanceDecember 28, 2022 | finance.yahoo.comInsulet's (PODD) Omnipod Sales Aid, Costs Continue to RiseSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PODD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter. Email Address PODD Company Calendar Last Earnings2/23/2023Today3/27/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:PODD CUSIP45784P10 CIK1145197 Webwww.insulet.com Phone(978) 600-7000Fax978-600-0120Employees2,600Year Founded2000Price Target and Rating Average Stock Price Forecast$317.82 High Stock Price Forecast$350.00 Low Stock Price Forecast$260.00 Forecasted Upside/Downside+2.5%Consensus RatingModerate Buy Rating Score (0-4)2.55 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$0.06 Trailing P/E Ratio5,169.50 Forward P/E Ratio240.44 P/E GrowthN/ANet Income$4.60 million Net Margins0.35% Pretax Margin0.75% Return on Equity20.55% Return on Assets4.24% Debt Debt-to-Equity Ratio2.88 Current Ratio3.60 Quick Ratio2.65 Sales & Book Value Annual Sales$1.31 billion Price / Sales16.52 Cash Flow$2.22 per share Price / Cash Flow139.60 Book Value$6.86 per share Price / Book45.21Miscellaneous Outstanding Shares69,540,000Free Float68,916,000Market Cap$21.57 billion OptionableOptionable Beta0.75 Social Links Key ExecutivesJames R. HollingsheadPresident, Chief Executive Officer & DirectorPrem SinghSenior Vice President-Global OperationsWayde Dwight McMillanChief Financial Officer, Treasurer & Executive VPTrang LySenior Vice President & Medical DirectorMichael P. SpearsSenior VP-Quality, Regulatory Affairs & ComplianceKey CompetitorsBaxter InternationalNYSE:BAXResMedNYSE:RMDTeleflexNYSE:TFXDexComNASDAQ:DXCMBecton, Dickinson andNYSE:BDXView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 110 shares on 3/23/2023Ownership: 0.006%B. Riley Wealth Advisors Inc.Bought 1,008 shares on 3/15/2023Ownership: 0.001%Charles AlpucheSold 23,401 sharesTotal: $7.14 M ($305.15/share)Victory Capital Management Inc.Sold 56,226 shares on 3/10/2023Ownership: 0.121%Charles AlpucheSold 4,000 sharesTotal: $1.16 M ($290.90/share)View All Insider TransactionsView All Institutional Transactions PODD Stock - Frequently Asked Questions Should I buy or sell Insulet stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PODD shares. View PODD analyst ratings or view top-rated stocks. What is Insulet's stock price forecast for 2023? 11 Wall Street analysts have issued 12-month target prices for Insulet's stock. Their PODD share price forecasts range from $260.00 to $350.00. On average, they predict the company's share price to reach $317.82 in the next year. This suggests a possible upside of 2.5% from the stock's current price. View analysts price targets for PODD or view top-rated stocks among Wall Street analysts. How have PODD shares performed in 2023? Insulet's stock was trading at $294.39 at the beginning of 2023. Since then, PODD stock has increased by 5.3% and is now trading at $310.00. View the best growth stocks for 2023 here. When is Insulet's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our PODD earnings forecast. How were Insulet's earnings last quarter? Insulet Co. (NASDAQ:PODD) issued its quarterly earnings data on Thursday, February, 23rd. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.31. The medical instruments supplier had revenue of $369.70 million for the quarter, compared to analysts' expectations of $331.73 million. Insulet had a net margin of 0.35% and a trailing twelve-month return on equity of 20.55%. Insulet's revenue for the quarter was up 20.1% on a year-over-year basis. During the same period last year, the company earned $0.42 earnings per share. What ETFs hold Insulet's stock? ETFs with the largest weight of Insulet (NASDAQ:PODD) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Goldman Sachs Future Health Care Equity ETF (GDOC), Fidelity Digital Health ETF (FDHT), Invesco Focused Discovery Growth ETF (IVDG), VictoryShares Nasdaq Next 50 ETF (QQQN), Harbor Health Care ETF (MEDI), BlackRock Future Innovators ETF (BFTR) and Hartford Large Cap Growth ETF (HFGO). What guidance has Insulet issued on next quarter's earnings? Insulet updated its first quarter 2023 earnings guidance on Thursday, February, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $327.89 million-$336.76 million, compared to the consensus revenue estimate of $333.86 million. What is Shacey Petrovic's approval rating as Insulet's CEO? 61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Insulet own? Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD). What is Insulet's stock symbol? Insulet trades on the NASDAQ under the ticker symbol "PODD." Who are Insulet's major shareholders? Insulet's stock is owned by a number of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (4.45%), Clearbridge Investments LLC (2.30%), Moneta Group Investment Advisors LLC (1.87%), Geode Capital Management LLC (1.38%), Fred Alger Management LLC (0.81%) and Allspring Global Investments Holdings LLC (0.65%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Corinne H Nevinny, Dan Manea, Eric Benjamin, John A Fallon, Michael P Spears, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan. View institutional ownership trends. How do I buy shares of Insulet? Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Insulet's stock price today? One share of PODD stock can currently be purchased for approximately $310.00. How much money does Insulet make? Insulet (NASDAQ:PODD) has a market capitalization of $21.56 billion and generates $1.31 billion in revenue each year. The medical instruments supplier earns $4.60 million in net income (profit) each year or $0.06 on an earnings per share basis. How many employees does Insulet have? The company employs 2,600 workers across the globe. How can I contact Insulet? Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for the company is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at ir@insulet.com, or via fax at 978-600-0120. This page (NASDAQ:PODD) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.